Why Drugs Fail in Phase 3: A Cytel Infographic

Posted by Esha Senchaudhuri

Jan 20, 2015 10:30:03 AM

According to a recent Cytel Whitepaper on Adaptive Clinical Trials, 50% of Phase 3 trials eventually fail. This new Cytel Infographicoffers a breakdown of why so many drugs fail in Phase 3.

The infographic demonstrates that while 42% of failures are economic (e.g. uncompetitive from the perspective of safety and efficacy), 45% of Phase 3 trials in fact fail for reasons of approvability. This includes inadequate safety and efficacy for FDA approval, issues with PK/bioavailability, and so forth. 

If anything the infographic highlights the importance of strategic clinical development during every phase of the trial, in order to avoid late phase pitfalls. 

Contact our Consultants Visit Cytel Consulting


Topics: Early Phase Trials, Clinical Development Strategy, Phase 3, Adaptive Clinical Trials

The Cytel blog keeps you up to speed with the latest developments in biostatistics and clinical biometrics.  Sign up for updates direct to your inbox. You can unsubscribe at any time.


Posts by Topic

see all

Recent Posts